Nucleic Acid, Nucleoside, or Nucleotide
CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%
Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes
Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership
gene therapy, Dependovirus, Transfer RNA, Partnership, Industry, research, Safety
Novartis to buy Regulus Therapeutics for up to $1.7B
Goldcrest, Novartis, Acquisition (action), Kidney Diseases
Lilly taps Creyon’s AI-enabled oligo tech in heavily backloaded $1B deal
Creyon, Eli Lilly, Eli, Oligonucleotides
As J&J aims to ‘fundamentally change’ how bladder cancer type is treated, ImmunityBio plays defense
TAR-200, bladder cancer, gemcitabine releasing system, non-muscle invasive bladder cancer (NMIBC), Johnson & Johnson, ImmunityBio, Anktiva, BCG-unresponsive, carcinoma in situ (CIS), bladder-sparing treatment
J&J reports durability data for bladder cancer ‘pretzel’ drug after FDA filing
Urinary Bladder, TAR 200, United States Food and Drug Administration, Malignant neoplasm of urinary bladder
Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects
Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%
Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies
Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies
Tome Bio founders wrangle jumping genes to create new programmable gene insertion tool
PGI, Technology, Retrotransposons, Clustered Regularly Interspaced Short Palindromic Repeats